Related Experiment Video

Updated: May 19, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity

Rodrigo Leite de Oliveira1, Sofie Deschoemaeker, Anne-Theres Henze

  • 1Lab of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, 3000 Leuven, Belgium.

Cancer Cell
|August 18, 2012
PubMed

Insights

Inactivating Prolyl hydroxylase domain protein 2 (PHD2) normalizes tumor vessels, improving chemotherapy delivery and efficacy. This strategy also protects healthy organs from chemotherapy side effects by enhancing detoxification pathways.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Chemotherapy efficacy is hindered by poor drug delivery to tumors and significant side-toxicity.
  • Prolyl hydroxylase domain protein 2 (PHD2) regulates cellular adaptation to stress and influences tumor vasculature.
  • Inhibiting PHD2 in endothelial cells can normalize tumor vessels, potentially improving drug delivery.

Purpose of the Study:

  • To investigate the impact of genetic inactivation of Phd2 on tumor vessel normalization and chemotherapy effectiveness.
  • To determine if Phd2 inhibition enhances chemotherapy's antitumor and antimetastatic effects.
  • To evaluate the protective role of Phd2 inhibition against chemotherapy-induced oxidative stress in healthy organs.

Main Methods:

  • Genetic inactivation of the Phd2 gene in endothelial cells.
  • Assessment of tumor vessel normalization and perfusion.
  • Evaluation of chemotherapeutic drug delivery to tumors.
  • Analysis of antitumor and antimetastatic effects of chemotherapy.
  • Pharmacological inhibition and genetic inactivation of Phd2 in response to oxidative stress.

Main Results:

  • Genetic inactivation of Phd2 normalized tumor vessels, significantly increasing chemotherapeutic drug delivery.
  • This normalization enhanced the antitumor and antimetastatic efficacy of chemotherapy, independent of Phd2 inhibition in cancer cells.
  • Phd2 inhibition or inactivation activated a hypoxia-inducible transcription factor (HIF)-mediated detoxification program in healthy organs.
  • This protective mechanism prevented chemotherapy-induced oxidative damage, organ failure, and tissue demise.

Conclusions:

  • Tumor vessel normalization via Phd2 inactivation is a viable strategy to optimize chemotherapy delivery and enhance its therapeutic index.
  • Targeting Phd2 offers a dual benefit: improving cancer treatment outcomes and mitigating chemotherapy-related toxicity in healthy tissues.
  • This study presents novel approaches for enhancing chemotherapy effectiveness and patient safety.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...